Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. More Details
Fair value with mediocre balance sheet.
Share Price & News
How has Travere Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TVTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: TVTX's weekly volatility (8%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: TVTX underperformed the US Biotechs industry which returned 23.1% over the past year.
Return vs Market: TVTX underperformed the US Market which returned 39.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Travere Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StTravere Therapeutics' (NASDAQ:TVTX) Shareholders Are Down 28% On Their Shares
2 months ago | Simply Wall StNeed To Know: Travere Therapeutics, Inc. (NASDAQ:TVTX) Insiders Have Been Selling Shares
3 months ago | Simply Wall StCould The Travere Therapeutics, Inc. (NASDAQ:TVTX) Ownership Structure Tell Us Something Useful?
Is Travere Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TVTX ($15.03) is trading below our estimate of fair value ($125.73)
Significantly Below Fair Value: TVTX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: TVTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: TVTX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TVTX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TVTX is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.4x).
How is Travere Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TVTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TVTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TVTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TVTX's revenue (31.8% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: TVTX's revenue (31.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TVTX's Return on Equity is forecast to be high in 3 years time
How has Travere Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TVTX is currently unprofitable.
Growing Profit Margin: TVTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TVTX is unprofitable, and losses have increased over the past 5 years at a rate of 38.7% per year.
Accelerating Growth: Unable to compare TVTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TVTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: TVTX has a negative Return on Equity (-61.79%), as it is currently unprofitable.
How is Travere Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: TVTX's short term assets ($565.0M) exceed its short term liabilities ($85.0M).
Long Term Liabilities: TVTX's short term assets ($565.0M) exceed its long term liabilities ($316.3M).
Debt to Equity History and Analysis
Debt Level: TVTX's debt to equity ratio (60.1%) is considered high.
Reducing Debt: TVTX's debt to equity ratio has increased from 13.8% to 60.1% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TVTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TVTX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Travere Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TVTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TVTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TVTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TVTX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TVTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Eric Dube (47 yo)
Dr. Eric M. Dube, Ph.D., serves as an Independent Director at Reneo Pharmaceuticals, Inc. since March 2021. Dr. Dube serves as President and Chief Executive Officer at Travere Therapeutics, Inc. (formerly ...
CEO Compensation Analysis
Compensation vs Market: Eric's total compensation ($USD5.45M) is above average for companies of similar size in the US market ($USD2.38M).
Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.
Experienced Management: TVTX's management team is considered experienced (3.1 years average tenure).
Experienced Board: TVTX's board of directors are considered experienced (4.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TVTX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.8%.
Travere Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Travere Therapeutics, Inc.
- Ticker: TVTX
- Exchange: NasdaqGM
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$928.630m
- Shares outstanding: 60.46m
- Website: https://www.travere.com
Number of Employees
- Travere Therapeutics, Inc.
- 3611 Valley Centre Drive
- Suite 300
- San Diego
- United States
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Che...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/18 03:57|
|End of Day Share Price||2021/06/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.